Figure 3. Interaction between Tregs and other cells in
HBV-related liver disease
References
[1] Seto W K, Lo Y R, Pawlotsky J
M,Yuen M F. Chronic hepatitis B virus infection [J]. Lancet,2018, 392 (10161): 2313-2324.
[2] Schweitzer A, Horn J,
Mikolajczyk R T, Krause G,Ott J J. Estimations of worldwide prevalence
of chronic hepatitis B virus infection: a systematic review of data
published between 1965 and 2013 [J]. Lancet, 2015, 386
(10003): 1546-1555.
[3] Zhan Q, Xu J H, Yu Y Y, Lo Kk
E, El-Nezami H,Zeng Z. Human immune repertoire in hepatitis B virus
infection [J]. World J Gastroenterol, 2021, 27 (25):
3790-3801.
[4] The global, regional, and
national burden of cirrhosis by cause in 195 countries and territories,
1990-2017: a systematic analysis for the Global Burden of Disease Study
2017 [J]. Lancet Gastroenterol Hepatol, 2020, 5 (3): 245-266.
[5] WHO Guidelines Approved
by the Guidelines Review Committee , in Guidelines for the
Prevention, Care and Treatment of Persons with Chronic Hepatitis B
Infection . 2015, World Health Organization, 2015.: Geneva.
[6] Shi Y,Zheng M. Hepatitis B
virus persistence and reactivation [J]. Nat Rev Immunol,2020, 370: m2200.
[7] Yuen M-F, Chen D-S, Dusheiko G
M, Janssen H L A, Lau D T Y, Locarnini S A, et al.Lai C-L. Hepatitis B
virus infection [J]. Nature Reviews Disease Primers, 2018, 4:
18035.
[8] Fattovich G, Bortolotti
F,Donato F. Natural history of chronic hepatitis B: special emphasis on
disease progression and prognostic factors [J]. J Hepatol,2008, 48 (2): 335-352.
[9] Choi Y S, Lee J, Lee H W,
Chang D Y, Sung P S, Jung M K, et al.Shin E C. Liver injury in acute
hepatitis A is associated with decreased frequency of regulatory T cells
caused by Fas-mediated apoptosis [J]. Gut, 2015, 64 (8):
1303-1313.
[10] Plitas G,Rudensky A Y.
Regulatory T Cells: Differentiation and Function [J]. Cancer Immunol
Res, 2016, 4 (9): 721-725.
[11] Sakaguchi S, Mikami N, Wing
J B, Tanaka A, Ichiyama K,Ohkura N. Regulatory T Cells and Human Disease
[J]. Annu Rev Immunol, 2020, 38: 541-566.
[12] Wing J B, Tanaka A,Sakaguchi
S. Human FOXP3(+) Regulatory T Cell Heterogeneity and Function in
Autoimmunity and Cancer [J]. Immunity, 2019, 50 (2): 302-316.
[13] Leonard J D, Gilmore D C,
Dileepan T, Nawrocka W I, Chao J L, Schoenbach M H, et al.Savage P A.
Identification of Natural Regulatory T Cell Epitopes Reveals Convergence
on a Dominant Autoantigen [J]. Immunity, 2017, 47 (1):
107-117.e108.
[14] Thornton A M, Lu J, Korty P
E, Kim Y C, Martens C, Sun P D,Shevach E M. Helios(+) and Helios(-) Treg
subpopulations are phenotypically and functionally distinct and express
dissimilar TCR repertoires [J]. Eur J Immunol, 2019, 49 (3):
398-412.
[15] Abbas A K, Benoist C,
Bluestone J A, Campbell D J, Ghosh S, Hori S, et al.Ziegler S F.
Regulatory T cells: recommendations to simplify the nomenclature
[J]. Nat Immunol, 2013, 14 (4): 307-308.
[16] Chen W, Jin W, Hardegen N,
Lei K J, Li L, Marinos N, et al.Wahl S M. Conversion of peripheral
CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta
induction of transcription factor Foxp3 [J]. J Exp Med, 2003,
198 (12): 1875-1886.
[17] Schmetterer K G,
Neunkirchner A,Pickl W F. Naturally occurring regulatory T cells:
markers, mechanisms, and manipulation [J]. Faseb j, 2012, 26
(6): 2253-2276.
[18] Fontenot J D, Gavin M
A,Rudensky A Y. Foxp3 programs the development and function of CD4+CD25+
regulatory T cells [J]. Nat Immunol, 2003, 4 (4): 330-336.
[19] Khattri R, Cox T, Yasayko S
A,Ramsdell F. An essential role for Scurfin in CD4+CD25+ T regulatory
cells [J]. Nat Immunol, 2003, 4 (4): 337-342.
[20] Hori S, Nomura T,Sakaguchi
S. Control of regulatory T cell development by the transcription factor
Foxp3 [J]. Science, 2003, 299 (5609): 1057-1061.
[21] Mills K H. Regulatory T
cells: friend or foe in immunity to infection? [J]. Nat Rev
Immunol, 2004, 4 (11): 841-855.
[22] Billerbeck E, Bottler
T,Thimme R. Regulatory T cells in viral hepatitis [J]. World J
Gastroenterol, 2007, 13 (36): 4858-4864.
[23] Liu W, Putnam A L, Xu-Yu Z,
Szot G L, Lee M R, Zhu S, et al.Bluestone J A. CD127 expression
inversely correlates with FoxP3 and suppressive function of human CD4+ T
reg cells [J]. J Exp Med, 2006, 203 (7): 1701-1711.
[24] Arroyo Hornero R, Betts G J,
Sawitzki B, Vogt K, Harden P N,Wood K J. CD45RA Distinguishes
CD4+CD25+CD127-/low TSDR Demethylated Regulatory T Cell Subpopulations
With Differential Stability and Susceptibility to Tacrolimus-Mediated
Inhibition of Suppression [J]. Transplantation, 2017, 101
(2): 302-309.
[25] Shitara K,Nishikawa H.
Regulatory T cells: a potential target in cancer immunotherapy [J].
Ann N Y Acad Sci, 2018, 1417 (1): 104-115.
[26] Marfil-Garza B A, Hefler J,
Bermudez De Leon M, Pawlick R, Dadheech N,Shapiro A M J. Progress in
Translational Regulatory T Cell Therapies for Type 1 Diabetes and Islet
Transplantation [J]. Endocr Rev, 2021, 42 (2): 198-218.
[27] Jin S, Sun S, Ling H, Ma J,
Zhang X, Xie Z, et al.Wang J. Protectin DX restores Treg/T(h)17 cell
balance in rheumatoid arthritis by inhibiting NLRP3 inflammasome via
miR-20a [J]. 2021, 12 (3): 280.
[28] Yang X, Lun Y, Jiang H, Liu
X, Duan Z, Xin S,Zhang J. SIRT1-Regulated Abnormal Acetylation of FOXP3
Induces Regulatory T-Cell Function Defect in Hashimoto’s Thyroiditis
[J]. Thyroid, 2018, 28 (2): 246-256.
[29] Zheng C, Zheng L, Yoo J K,
Guo H, Zhang Y, Guo X, et al.Zhang Z. Landscape of Infiltrating T Cells
in Liver Cancer Revealed by Single-Cell Sequencing [J]. Cell,2017, 169 (7): 1342-1356.e1316.
[30] Ichai P,Samuel D. Management
of Fulminant Hepatitis B [J]. Curr Infect Dis Rep, 2019, 21
(7): 25.
[31] Liang T J. Hepatitis B: the
virus and disease [J]. Hepatology, 2009, 49 (5 Suppl):
S13-21.
[32] Wright T L,Lau J Y. Clinical
aspects of hepatitis B virus infection [J]. Lancet, 1993, 342
(8883): 1340-1344.
[33] Mason W S, Gill U S, Litwin
S, Zhou Y, Peri S, Pop O, et al.Kennedy P T. HBV DNA Integration and
Clonal Hepatocyte Expansion in Chronic Hepatitis B Patients Considered
Immune Tolerant [J]. Gastroenterology, 2016, 151 (5):
986-998.e984.
[34] Vignali D A, Collison L
W,Workman C J. How regulatory T cells work [J]. Nat Rev
Immunol, 2008, 8 (7): 523-532.
[35] Park R, Winnicki M, Liu
E,Chu W M. Immune checkpoints and cancer in the immunogenomics era
[J]. Brief Funct Genomics, 2019, 18 (2): 133-139.
[36] Qureshi O S, Zheng Y,
Nakamura K, Attridge K, Manzotti C, Schmidt E M, et al.Sansom D M.
Trans-endocytosis of CD80 and CD86: a molecular basis for the
cell-extrinsic function of CTLA-4 [J]. Science, 2011, 332
(6029): 600-603.
[37] Chikuma S. CTLA-4, an
Essential Immune-Checkpoint for T-Cell Activation [J]. Curr Top
Microbiol Immunol, 2017, 410: 99-126.
[38] Grover P, Goel P N,Greene M
I. Regulatory T Cells: Regulation of Identity and Function [J].
Front Immunol, 2021, 12: 750542.
[39] Arce-Sillas A,
Álvarez-Luquín D D, Tamaya-Domínguez B, Gomez-Fuentes S, Trejo-García A,
Melo-Salas M, et al.Adalid-Peralta L. Regulatory T Cells: Molecular
Actions on Effector Cells in Immune Regulation [J]. J Immunol
Res, 2016, 2016: 1720827.
[40] Klocke K, Sakaguchi S,
Holmdahl R,Wing K. Induction of autoimmune disease by deletion of CTLA-4
in mice in adulthood [J]. 2016, 113 (17): E2383-2392.
[41] PD-L1 regulates the
development m, and function of induced regulatory T cellsSheppard, K.
A., Fitz L J, Lee J M, Benander C, George J A, Wooters J, et
al.Chaudhary D. PD-1 inhibits T-cell receptor induced phosphorylation of
the ZAP70/CD3zeta signalosome and downstream signaling to PKCtheta
[J]. FEBS Lett, 2004, 574 (1-3): 37-41.
[42] CD73 as a potential
opportunity for cancer immunotherapyFrancisco L M, Salinas V H, Brown K
E, Vanguri V K, Freeman G J, Kuchroo V K,Sharpe A H. PD-L1 regulates the
development, maintenance, and function of induced regulatory T cells
[J]. J Exp Med, 2009, 206 (13): 3015-3029.
[43] Ghalamfarsa G,Kazemi M H.
CD73 as a potential opportunity for cancer immunotherapy [J]. Expert
Opin Ther Targets, 2019, 23 (2): 127-142.
[44] Allard B, Longhi M S, Robson
S C,Stagg J. The ectonucleotidases CD39 and CD73: Novel checkpoint
inhibitor targets [J]. Immunol Rev, 2017, 276 (1): 121-144.
[45] Antonioli L, Pacher P, Vizi
E S,Haskó G. CD39 and CD73 in immunity and inflammation [J]. Trends
Mol Med, 2013, 19 (6): 355-367.
[46] Gavin M A, Rasmussen J P,
Fontenot J D, Vasta V, Manganiello V C, Beavo J A,Rudensky A Y.
Foxp3-dependent programme of regulatory T-cell differentiation [J].
Nature, 2007, 445 (7129): 771-775.
[47] Cekic C,Linden J. Purinergic
regulation of the immune system [J]. Nat Rev Immunol, 2016,
16 (3): 177-192.
[48] Huang C T, Workman C J,
Flies D, Pan X, Marson A L, Zhou G, et al.Vignali D A. Role of LAG-3 in
regulatory T cells [J]. Immunity, 2004, 21 (4): 503-513.
[49] Yang Z Z, Kim H J, Wu H,
Jalali S,Tang X. TIGIT Expression Is Associated with T-cell Suppression
and Exhaustion and Predicts Clinical Outcome and Anti-PD-1 Response in
Follicular Lymphoma [J]. Clin Cancer Res, 2020, 26 (19):
5217-5231.
[50] Manieri N A, Chiang E
Y,Grogan J L. TIGIT: A Key Inhibitor of the Cancer Immunity Cycle
[J]. Trends Immunol, 2017, 38 (1): 20-28.
[51] TIGIT as a Promising
Therapeutic Target in Autoimmune DiseasesTIGIT as a Promising
Therapeutic Target in Autoimmune DiseasesStanietsky N, Rovis T L,
Glasner A, Seidel E, Tsukerman P, Yamin R, et al.Mandelboim O. Mouse
TIGIT inhibits NK-cell cytotoxicity upon interaction with PVR [J].
Eur J Immunol, 2013, 43 (8): 2138-2150.
[52] Yue C, Gao S, Li S, Xing Z,
Qian H, Hu Y, et al.Hua C. TIGIT as a Promising Therapeutic Target in
Autoimmune Diseases [J]. Front Immunol, 2022, 13: 911919.
[53] Huang Y H, Zhu C, Kondo Y,
Anderson A C, Gandhi A, Russell A, et al.Blumberg R S. CEACAM1 regulates
TIM-3-mediated tolerance and exhaustion [J]. Nature, 2015,
517 (7534): 386-390.
[54] CD73 expression on
extracellular vesicles derived from CD4+ CD25+ Foxp3+CD73 expression on
extracellular vesicles derived from CD4+ CD25+ Foxp3+Liu Z, McMichael E
L, Shayan G, Li J, Chen K, Srivastava R, et al.Ferris R L. Novel
Effector Phenotype of Tim-3(+) Regulatory T Cells Leads to Enhanced
Suppressive Function in Head and Neck Cancer Patients [J]. Clin
Cancer Res, 2018, 24 (18): 4529-4538.
[55] Smyth L A, Ratnasothy K,
Tsang J Y, Boardman D, Warley A, Lechler R,Lombardi G. CD73 expression
on extracellular vesicles derived from CD4+ CD25+ Foxp3+ T cells
contributes to their regulatory function [J]. Eur J Immunol,2013, 43 (9): 2430-2440.
[56] Changes in circulating TCF1-
and GARP-associated regulatory T cell subsets reflect the
clinicalInvestigation of Regulatory T Cells and Secreted Tuyji Tok Y,
Şener A G, Aksoy Gökmen A, Demirdal T,Kaya S. [Investigation of
Regulatory T Cells and Secreted Immunomodulatory Cytokine IL-10 Levels
in Patients with Hepatitis B] [J]. Mikrobiyol Bul, 2020, 54
(2): 266-278.
[57] Shao X, Ma J, Jia S, Yang L,
Wang W,Jin Z. Interleukin-35 Suppresses Antiviral Immune Response in
Chronic Hepatitis B Virus Infection [J]. Front Cell Infect
Microbiol, 2017, 7: 472.
[58] Qiu H, Wang N, Lin D, Yuan
Y, Li J, Mao D,Meng Y. The positive feedback loop of furin and TGFβ1
enhances the immune responses of Tregs to hepatocellular carcinoma cells
and hepatitis B virus in vitro [J]. Cell Biol Int, 2022, 46
(8): 1215-1226.
[59] Li X, Liu X,Wang W. IL-35: A
Novel Immunomodulator in Hepatitis B Virus-Related Liver Diseases
[J]. Front Cell Dev Biol, 2021, 9: 614847.
[60] Thornton A M, Donovan E E,
Piccirillo C A,Shevach E M. Cutting edge: IL-2 is critically required
for the in vitro activation of CD4+CD25+ T cell suppressor function
[J]. J Immunol, 2004, 172 (11): 6519-6523.
[61] Zhao H, Liao X,Kang Y.
Tregs: Where We Are and What Comes Next? [J]. Front Immunol,2017, 8: 1578.
[62] Zhao H J, Hu Y F, Han Q
J,Zhang J. Innate and adaptive immune escape mechanisms of hepatitis B
virus [J]. Cancers (Basel), 2022, 28 (9): 881-896.
[63] Yang G, Wan P, Zhang Y, Tan
Q, Qudus M S, Yue Z, et al.Li Y. Innate Immunity, Inflammation, and
Intervention in HBV Infection [J]. 2022, 14 (10).
[64] Zheng J, Ou Z, Xu Y, Xia Z,
Lin X, Jin S, et al.Wu J. Hepatitis B virus-specific effector CD8(+) T
cells are an important determinant of disease prognosis: A meta-analysis
[J]. Vaccine, 2019, 37 (18): 2439-2446.
[65] Asabe S, Wieland S F,
Chattopadhyay P K, Roederer M, Engle R E, Purcell R H,Chisari F V. The
size of the viral inoculum contributes to the outcome of hepatitis B
virus infection [J]. J Virol, 2009, 83 (19): 9652-9662.
[66] Shin E C, Sung P S,Park S H.
Immune responses and immunopathology in acute and chronic viral
hepatitis [J]. Nat Rev Immunol, 2016, 16 (8): 509-523.
[67] Guidotti L G, Rochford R,
Chung J, Shapiro M, Purcell R,Chisari F V. Viral clearance without
destruction of infected cells during acute HBV infection [J].
Science, 1999, 284 (5415): 825-829.
[68] Xia Y, Stadler D, Lucifora
J, Reisinger F, Webb D, Hösel M, et al.Protzer U. Interferon-γ and Tumor
Necrosis Factor-α Produced by T Cells Reduce the HBV Persistence Form,
cccDNA, Without Cytolysis [J]. Gastroenterology, 2016, 150
(1): 194-205.
[69] Stoop J N, van der Molen R
G, Baan C C, van der Laan L J, Kuipers E J, Kusters J G,Janssen H L.
Regulatory T cells contribute to the impaired immune response in
patients with chronic hepatitis B virus infection [J].
Hepatology, 2005, 41 (4): 771-778.
[70] Feng I C, Koay L B, Sheu M
J, Kuo H T, Sun C S, Lee C, et al.Tsai S L. HBcAg-specific CD4+CD25+
regulatory T cells modulate immune tolerance and acute exacerbation on
the natural history of chronic hepatitis B virus infection [J]. J
Biomed Sci, 2007, 14 (1): 43-57.
[71] TrehanPati N, Geffers R,
Sukriti, Hissar S, Riese P, Toepfer T, et al.Sarin S K. Gene
expression signatures of peripheral CD4+ T cells clearly
discriminate between patients with acute and chronic hepatitis B
infection [J]. Hepatology, 2009, 49 (3): 781-790.
[72] Peng G, Li S, Wu W, Sun Z,
Chen Y,Chen Z. Circulating CD4+ CD25+ regulatory T cells correlate with
chronic hepatitis B infection [J]. Immunology, 2008, 123 (1):
57-65.
[73] Xu D, Fu J, Jin L, Zhang H,
Zhou C, Zou Z, et al.Wang F S. Circulating and liver resident CD4+CD25+
regulatory T cells actively influence the antiviral immune response and
disease progression in patients with hepatitis B [J]. J
Immunol, 2006, 177 (1): 739-747.
[74] Characterization of the Treg
Response in the Hepatitis B Virus Hydrodynamic Injection MouseStross L,
Günther J, Gasteiger G, Asen T, Graf S, Aichler M, et al.Protzer U.
Foxp3+ regulatory T cells protect the liver from immune damage and
compromise virus control during acute experimental hepatitis B virus
infection in mice [J]. Hepatology, 2012, 56 (3): 873-883.
[75] Dietze K K, Schimmer S,
Kretzmer F, Wang J, Lin Y, Huang X, et al.Liu J. Characterization of the
Treg Response in the Hepatitis B Virus Hydrodynamic Injection Mouse
Model [J]. PLoS One, 2016, 11 (3): e0151717.
[76] Kosinska A D, Pishraft-Sabet
L, Wu W, Fang Z, Lenart M, Chen J, et al.Lu M. Low hepatitis B
virus-specific T-cell response in males correlates with high regulatory
T-cell numbers in murine models [J]. Hepatology, 2017, 66
(1): 69-83.
[77] Zou S,Du Y. Simultaneous or
Prior Activation of Intrahepatic Type I Interferon Signaling Leads to
Hepatitis B Virus Persistence in a Mouse Model [J]. 2021, 95 (24):
e0003421.
[78] Littman D R,Rudensky A Y.
Th17 and regulatory T cells in mediating and restraining inflammation
[J]. Cell, 2010, 140 (6): 845-858.
[79] Zelinskyy G, Dietze K,
Sparwasser T,Dittmer U. Regulatory T cells suppress antiviral immune
responses and increase viral loads during acute infection with a
lymphotropic retrovirus [J]. PLoS Pathog, 2009, 5 (8):
e1000406.
[80] Xu L, Xia C, Long Y, Liu C,
Lu S, Song Y, et al.Zou W. Regulatory T cells and T helper 17 cells in
viral infection [J]. Hepatol Res, 2020, 91 (5): e12873.
[81] Cheng X, Shan Y Y,Luo Y W.
[Dynamic change in Th17/regulatory T cell ratio in peripheral blood of
patients with acute hepatitis B and its significance] [J].
Zhonghua Gan Zang Bing Za Zhi, 2016, 24 (8): 565-568.
[82] Bahabayi A, Zeng X,
Tuerhanbayi B, Zhang Y, Hasimu A, Guo S, et al.Liu C. Changes in
circulating TCF1- and GARP-associated regulatory T cell subsets reflect
the clinical status of patients with chronic HBV infection [J].
2022, 211 (5-6): 237-247.
[83] Liu C. Increased proportion
of functional subpopulations in circulating regulatory T cells in
patients with chronic hepatitis B [J]. Medicine (Baltimore),2020, 50 (4): 439-452.
[84] Tang R, Lei Z, Wang X, Qi Q,
He J, Liu D, et al.Su C. Hepatitis B envelope antigen increases Tregs by
converting CD4+CD25(-) T cells into CD4(+)CD25(+)Foxp3(+) Tregs [J].
Exp Ther Med, 2020, 20 (4): 3679-3686.
[85] Giadans C G, Ríos D A,
Ameigeiras B, Pietrantonio A M, Lucatelli N L, Haddad L, et al.Preciado
M V. Chronic hepatitis B: The interplay between intrahepatic lymphocyte
population and viral antigens in relation to liver damage [J]. J
Viral Hepat, 2019, 26 (6): 727-737.
[86] Li J, Qiu S J, She W M, Wang
F P, Gao H, Li L, et al.Jiang W. Significance of the balance between
regulatory T (Treg) and T helper 17 (Th17) cells during hepatitis B
virus related liver fibrosis [J]. PLoS One, 2012, 7 (6):
e39307.
[87] Niu Y, Liu H, Yin D, Yi R,
Chen T, Xue H, et al.Zhao Y. The balance between intrahepatic IL-17(+) T
cells and Foxp3(+) regulatory T cells plays an important role in
HBV-related end-stage liver disease [J]. BMC Immunol, 2011,
12: 47.
[88] Zeng X, Bahabayi A,
Tuerhanbayi B, Zheng M, Liu T, Xu L, et al.Liu C. The altered HLA-DQ
expression in peripheral blood T cells of chronic hepatitis B patients
characterizes the function of T cells [J]. Med Microbiol
Immunol, 2022, 29 (5): 340-351.
[89] chronic hepatitis B
Franzese, O. R T c a I-T h c e i p w c h B R T c a I-T h c e i p w,
Kennedy P T, Gehring A J, Gotto J, Williams R, Maini M K,Bertoletti A.
Modulation of the CD8+-T-cell response by CD4+ CD25+ regulatory T cells
in patients with hepatitis B virus infection [J]. J Virol,2005, 79 (6): 3322-3328.
[90] Feng H, Yin J, Han Y P, Zhou
X Y, Chen S, Yang L, et al.Zhang G X. Regulatory T cells and IL-17(+) T
helper cells enhanced in patients with chronic hepatitis B virus
infection [J]. Int J Clin Exp Med, 2015, 8 (6): 8674-8685.
[91] Ichikawa S, Mucida D, Tyznik
A J, Kronenberg M,Cheroutre H. Hepatic stellate cells function as
regulatory bystanders [J]. J Immunol, 2011, 186 (10):
5549-5555.
[92] Up-regulated DNA-binding
inhibitor Id3 promotes differentiation of regulatoryLi W, Han J,Wu H.
Regulatory T-cells promote hepatitis B virus infection and
hepatocellular carcinoma progression [J]. Chronic Dis Transl
Med, 2016, 2 (2): 67-80.
[93] Liu C, Zeng X, Yu S, Ren L,
Sun X, Long Y, et al.Zhang Y. Up-regulated DNA-binding inhibitor Id3
promotes differentiation of regulatory T cell to influence antiviral
immunity in chronic hepatitis B virus infection [J]. Life
Sci, 2021, 285: 119991.
[94] Al-Bari M A A. A current
view of molecular dissection in autophagy machinery [J]. J Physiol
Biochem, 2020, 76 (3): 357-372.
[95] Wei J, Long L, Yang K, Guy
C, Shrestha S, Chen Z, et al.Chi H. Autophagy enforces functional
integrity of regulatory T cells by coupling environmental cues and
metabolic homeostasis [J]. Nat Immunol, 2016, 17 (3):
277-285.
[96] Cheng L S, Li J, Liu Y, Wang
F P, Wang S Q, She W M, et al.Jiang W. HMGB1-induced autophagy: a new
pathway to maintain Treg function during chronic hepatitis B virus
infection [J]. Clin Sci (Lond), 2017, 131 (5): 381-394.
[97] Hu C C, Jeng W J, Chen Y C,
Fang J H, Huang C H, Teng W, et al.Chien R N. Memory Regulatory T cells
Increase Only In Inflammatory Phase of Chronic Hepatitis B Infection and
Related to Galectin-9/Tim-3 interaction [J]. Sci Rep, 2017, 7
(1): 15280.
[98] Hong J,Gong Z J. Human
plasmacytoid dendritic cells from patients with chronic hepatitis B
virus infection induce the generation of a higher proportion of CD4(+)
and CD25(+) regulatory T cells compared with healthy patients [J].
Hepatol Res, 2008, 38 (4): 362-373.
[99] Acute-on-chronic liver
failure: terminology m a m, Y., Yuan X D, Liu H H, Xiang L, Chen L M,
Fan Y C, et al.Wang K. 5-Aza-2’-deoxycytidine may enhance the frequency
of T regulatory cells from CD4(+) naïve T cells isolated from the
peripheral blood of patients with chronic HBV infection [J]. Clin
Exp Immunol, 2021, 17 (2): 177-185.
[100] Sarin S K,Choudhury A.
Acute-on-chronic liver failure: terminology, mechanisms and management
[J]. Nat Rev Gastroenterol Hepatol, 2016, 13 (3): 131-149.
[101] Chen T, Yang Z, Choudhury
A K, Al Mahtab M, Li J, Chen Y, et al.Ning Q. Complications constitute a
major risk factor for mortality in hepatitis B virus-related
acute-on-chronic liver failure patients: a multi-national study from the
Asia-Pacific region [J]. Hepatol Int, 2019, 13 (6): 695-705.
[102] Wang F, Sun W, Xiao Q,
Liang C, Jiang S, Lian Y, et al.Zheng S. Peripheral T lymphocytes
predict the severity and prognosis in patients with HBV-related
acute-on-chronic liver failure [J]. Medicine (Baltimore),2021, 100 (5): e24075.
[103] Yang L, Jia S, Shao X, Liu
S, Zhang Q, Song J, et al.Jin Z. Interleukin-35 modulates the balance
between viral specific CD4(+)CD25(+)CD127(dim/-) regulatory T cells and
T helper 17 cells in chronic hepatitis B virus infection [J]. Virol
J, 2019, 16 (1): 48.
[104] Tan N H, Chen B, J. P,S.
D. Treg/Th17 Cell Balance in Patients with Hepatitis B Virus-Related
Acute-on-Chronic Liver Failure at Different Disease Stages [J].
Biomed Res Int, 2021, 2021: 9140602.
[105] Xue-Song L, Cheng-Zhong L,
Ying Z,Mo-Bin W. Changes of Treg and Th17 cells balance in the
development of acute and chronic hepatitis B virus infection [J].
BMC Gastroenterol, 2012, 12: 43.
[106] Liang X S, Li C Z, Zhou Y,
Yin W, Liu Y Y,Fan W H. Changes in circulating Foxp3(+) regulatory T
cells and interleukin-17-producing T helper cells during HBV-related
acute-on-chronic liver failure [J]. World J Gastroenterol,2014, 20 (26): 8558-8571.
[107] Niu Y H, Yin D L, Liu H L,
Yi R T, Yang Y C, Xue H A, et al.Zhao Y R. Restoring the Treg cell to
Th17 cell ratio may alleviate HBV-related acute-on-chronic liver failure
[J]. World J Gastroenterol, 2013, 19 (26): 4146-4154.
[108] Zhang G L, Xie D Y, Lin B
L, Xie C, Ye Y N, Peng L, et al.Gao Z L. Imbalance of
interleukin-17-producing CD4 T cells/regulatory T cells axis occurs in
remission stage of patients with hepatitis B virus-related
acute-on-chronic liver failure [J]. 4.3-J Gastroenterol
Hepatol, 2013, 28 (3): 513-521.
[109] Mak L Y, Cheung K S, Fung
J, Seto W K,Yuen M F. New strategies for the treatment of chronic
hepatitis B [J]. Trends Mol Med, 2022, 28 (9): 742-757.
[110] Jiang Y, Li W, Yu L, Liu
J, Xin G, Yan H, et al.Niu J. Enhancing the antihepatitis B virus immune
response by adefovir dipivoxil and entecavir therapies [J]. 22-Cell
Mol Immunol, 2011, 8 (1): 75-82.
[111] Pang X, Zhang L, Liu N,
Liu B, Chen Z, Li H, et al.Hu P. Combination of pegylated
interferon-alpha and nucleos(t)ide analogue treatment enhances the
activity of natural killer cells in nucleos(t)ide analogue experienced
chronic hepatitis B patients [J]. Clin Exp Immunol, 2020, 202
(1): 80-92.
[112] Zhang Y R, Li B, Wang C X,
Zhou N, Qi W, Li X L, et al.Zhang Y D. Influence of Treg cells and HBV
genotype on sustained response and drug resistance in the treatment with
nucleoside drugs [J]. Braz J Med Biol Res, 2017, 50 (3):
e5796.
[113] Lan Y T, Wang Z L, Tian P,
Gong X N, Fan Y C,Wang K. Treg/Th17 imbalance and its clinical
significance in patients with hepatitis B-associated liver cirrhosis
[J]. Scand J Immunol, 2019, 14 (1): 114.
[114] Liu N, Liu B, Zhang L, Li
H, Chen Z, Luo A, et al.Hu P. Recovery of circulating CD56(dim) NK cells
and the balance of Th17/Treg after nucleoside analog therapy in patients
with chronic hepatitis B and low levels of HBsAg [J]. Int
Immunopharmacol, 2018, 62: 59-66.
[115] Wang D, Fu B, Shen X, Guo
C, Liu Y, Zhang J, et al.Wei H. Restoration of HBV-specific CD8(+)
T-cell responses by sequential low-dose IL-2 treatment in non-responder
patients after IFN-α therapy [J]. Can J Gastroenterol
Hepatol, 2021, 6 (1): 376.
[116] Alberts C J, Clifford G M,
Georges D, Negro F, Lesi O A, Hutin Y J,de Martel C. Worldwide
prevalence of hepatitis B virus and hepatitis C virus among patients
with cirrhosis at country, region, and global levels: a systematic
review [J]. Lancet Gastroenterol Hepatol, 2022, 7 (8):
724-735.
[117] Deng Z, Zhou J, Mu X, Gu
J, Li X, Shao Q, et al.Xia Y. Regulatory T Cells Improved the
Anti-cirrhosis Activity of Human Amniotic Mesenchymal Stem Cell in the
Liver by Regulating the TGF-β-Indoleamine 2,3-Dioxygenase Signaling
[J]. Front Cell Dev Biol, 2021, 9: 737825.
[118] Cho H J,JY. C. Role of
Immune Cells in Patients with Hepatitis B Virus-Related Hepatocellular
Carcinoma [J]. Int J Mol Sci, 2021, 22 (15): 8011.
[119] Li X, Su Y, Hua X, Xie C,
Liu J, Huang Y, et al.Gao Z. Levels of hepatic Th17 cells and regulatory
T cells upregulated by hepatic stellate cells in advanced HBV-related
liver fibrosis [J]. J Transl Med, 2017, 15 (1): 75.
[120] Moreau J M, Velegraki M,
Bolyard C, Rosenblum M D,Li Z. Transforming growth factor-β1 in
regulatory T cell biology [J]. Sci Immunol, 2022, 7 (69):
eabi4613.
[121] Huang Y H, Chen Y X, Zhang
L J, Chen Z X,Wang X Z. Hydrodynamics-based transfection of rat
interleukin-10 gene attenuates porcine serum-induced liver fibrosis in
rats by inhibiting the activation of hepatic stellate cells [J]. Int
J Mol Med, 2014, 34 (3): 677-686.
[122] Yu X, Guo R, Ming D, Su M,
Lin C, Deng Y, et al.Su Z. Ratios of regulatory T cells/T-helper 17
cells and transforming growth factor-β1/interleukin-17 to be associated
with the development of hepatitis B virus-associated liver cirrhosis
[J]. J Gastroenterol Hepatol, 2014, 29 (5): 1065-1072.
[123] Li K, Liu H,Guo T.
Th17/Treg imbalance is an indicator of liver cirrhosis process and a
risk factor for HCC occurrence in HBV patients [J]. Clin Res Hepatol
Gastroenterol, 2017, 41 (4): 399-407.
[124] Mou H, Wu S, Zhao G,Wang
J. Changes of Th17/Treg ratio in the transition of chronic hepatitis B
to liver cirrhosis and correlations with liver function and inflammation
[J]. Exp Ther Med, 2019, 17 (4): 2963-2968.
[125] Sagnelli E,Macera M.
Epidemiological and etiological variations in hepatocellular carcinoma
[J]. Infection, 2020, 48 (1): 7-17.
[126] Lim C J, Lee Y H, Pan L,
Lai L, Chua C, Wasser M, et al.Chew V. Multidimensional analyses reveal
distinct immune microenvironment in hepatitis B virus-related
hepatocellular carcinoma [J]. Gut, 2019, 68 (5): 916-927.
[127] Wada Y, Nakashima O,
Kutami R, Yamamoto O,Kojiro M. Clinicopathological study on
hepatocellular carcinoma with lymphocytic infiltration [J].
Hepatology, 1998, 27 (2): 407-414.
[128] Fu J, Xu D, Liu Z, Shi M,
Zhao P, Fu B, et al.Wang F S. Increased regulatory T cells correlate
with CD8 T-cell impairment and poor survival in hepatocellular carcinoma
patients [J]. Gastroenterology, 2007, 132 (7): 2328-2339.
[129] Zhang H H, Mei M H, Fei R,
Liu F, Wang J H, Liao W J, et al.Chen H S. Regulatory T cells in chronic
hepatitis B patients affect the immunopathogenesis of hepatocellular
carcinoma by suppressing the anti-tumour immune responses [J]. J
Viral Hepat, 2010, 17 Suppl 1: 34-43.
[130] Zhang X, Gao L, Liang X,
Guo M, Wang R, Pan Y, et al.Ma C. HBV preS2 transactivates FOXP3
expression in malignant hepatocytes [J]. Liver Int, 2015, 35
(3): 1087-1094.
[131] Tough D F, Rioja I, Modis
L K,Prinjha R K. Epigenetic Regulation of T Cell Memory: Recalling
Therapeutic Implications [J]. Trends Immunol, 2020, 41 (1):
29-45.
[132] Nishida N, Kudo M, Gao Y,
You M, Fu J, Tian M, et al.Yang P. Intratumoral stem-like CCR4+
regulatory T cells orchestrate the immunosuppressive microenvironment in
HCC associated with hepatitis B [J]. J Histochem Cytochem,2022, 76 (1): 148-159.
[133] Yang P, Li Q J, Feng Y,
Zhang Y, Markowitz G J, Ning S, et al.Wang X F. TGF-β-miR-34a-CCL22
signaling-induced Treg cell recruitment promotes venous metastases of
HBV-positive hepatocellular carcinoma [J]. Cancer Cell, 2012,
22 (3): 291-303.
[134] Zhang C, Gao Y, Du
C,Markowitz G J. Hepatitis B-Induced IL8 Promotes Hepatocellular
Carcinoma Venous Metastasis and Intrahepatic Treg Accumulation [J].
Biomed Res Int, 2021, 81 (9): 2386-2398.
[135] Tian Z, Chen Y,Gao B.
Natural killer cells in liver disease [J]. Hepatology, 2013,
57 (4): 1654-1662.
[136] Chen Y, Sun R, Wu X, Cheng
M, Wei H,Tian Z. CD4+CD25+ Regulatory T Cells Inhibit Natural Killer
Cell Hepatocytotoxicity of Hepatitis B Virus Transgenic Mice via
Membrane-Bound TGF-β and OX40 [J]. J Innate Immun, 2016, 8
(1): 30-42.
[137] Liu N, Chang C W, Steer C
J, Wang X W,Song G. MicroRNA-15a/16-1 Prevents Hepatocellular Carcinoma
by Disrupting the Communication Between Kupffer Cells and Regulatory T
Cells [J]. Gastroenterology, 2022, 162 (2): 575-589.
[138] Wu Q, Zhou W, Yin S, Zhou
Y, Chen T, Qian J, et al.Zheng S. Blocking Triggering Receptor Expressed
on Myeloid Cells-1-Positive Tumor-Associated Macrophages Induced by
Hypoxia Reverses Immunosuppression and Anti-Programmed Cell Death Ligand
1 Resistance in Liver Cancer [J]. Sci Rep, 2019, 70 (1):
198-214.
[139] Dawidowicz M, Kula A,
Mielcarska S,Kiczmer P. B7H4 Expression Is More Frequent in MSS Status
Colorectal Cancer and Is Negatively Associated with Tumour Infiltrating
Lymphocytes [J]. cells, 2023, 12 (6): 861.
[140] Kryczek I, Wei S, Zou L,
Zhu G, Mottram P, Xu H, et al.Zou W. Cutting edge: induction of B7-H4 on
APCs through IL-10: novel suppressive mode for regulatory T cells
[J]. J Immunol, 2006, 177 (1): 40-44.
[141] Yu X, Harden K, Gonzalez L
C, Francesco M, Chiang E, Irving B, et al.Grogan J L. The surface
protein TIGIT suppresses T cell activation by promoting the generation
of mature immunoregulatory dendritic cells [J]. Nat Immunol,2009, 10 (1): 48-57.
[142] Zheng M, Sun R, Wei H,Tian
Z. NK Cells Help Induce Anti-Hepatitis B Virus CD8+ T Cell Immunity in
Mice [J]. J Immunol, 2016, 196 (10): 4122-4131.
[143] Liu S, Xu C, Yang F, Zong
L, Qin Y, Gao Y, et al.Zheng M. Natural Killer Cells Induce CD8(+) T
Cell Dysfunction via Galectin-9/TIM-3 in Chronic Hepatitis B Virus
Infection [J]. Front Immunol, 2022, 13: 884290.
[144] Ma Q, Dong X, Liu S, Zhong
T, Sun D, Zong L, et al.Zheng M. Hepatitis B e Antigen Induces NKG2A(+)
Natural Killer Cell Dysfunction via Regulatory T Cell-Derived
Interleukin 10 in Chronic Hepatitis B Virus Infection [J]. Front
Cell Dev Biol, 2020, 8: 421.
[145] Sun C, Xu J, Huang Q,
Huang M, Wen H, Zhang C, et al.Tian Z. High NKG2A expression contributes
to NK cell exhaustion and predicts a poor prognosis of patients with
liver cancer [J]. Oncoimmunology, 2017, 6 (1): e1264562.
[146] Romano M, Fanelli G,
Albany C J, Giganti G,Lombardi G. Past, Present, and Future of
Regulatory T Cell Therapy in Transplantation and Autoimmunity [J].
Front Immunol, 2019, 10: 43.
[147] Topalian S L, Drake C
G,Pardoll D M. Immune checkpoint blockade: a common denominator approach
to cancer therapy [J]. Cancer Cell, 2015, 27 (4): 450-461.
[148] Langhans B. Role of
regulatory T cells and checkpoint inhibition in hepatocellular carcinoma
[J]. Cancer Med, 2019, 68 (12): 2055-2066.
[149] Wu J F, Wu T C, Chen C H,
Ni Y H, Chen H L, Hsu H Y,Chang M H. Serum levels of interleukin-10 and
interleukin-12 predict early, spontaneous hepatitis B virus e antigen
seroconversion [J]. Gastroenterology, 2010, 138 (1):
165-172.e161-163.
[150] Karkhah A, Javanian
M,Ebrahimpour S. The role of regulatory T cells in immunopathogenesis
and immunotherapy of viral infections [J]. Infect Genet Evol,2018, 59: 32-37.
[151] Wen H, Liu Y, Wang S, Wang
T, Zhang G, Chen X, et al.Cui H. Design and Synthesis of Indoleamine
2,3-Dioxygenase 1 Inhibitors and Evaluation of Their Use as Anti-Tumor
Agents [J]. Molecules, 2019, 24 (11).
[152] He W, Hao S, Dong X, Zhang
D,Jia Z. Circulating cytokine profile and modulation of regulatory T
cells in chronic hepatitis B patients with type 2 diabetes mellitus
[J]. Biomol Biomed, 2022, 23 (1): 53-62.
[153] Huang M, Huang X,Huang N.
Exosomal circGSE1 promotes immune escape of hepatocellular carcinoma by
inducing the expansion of regulatory T cells [J]. Cancer Sci,2022, 113 (6): 1968-1983.
[154] Kim H D, Song G W, Park S,
Jung M K, Kim M H, Kang H J, et al.Park S H. Association Between
Expression Level of PD1 by Tumor-Infiltrating CD8(+) T Cells and
Features of Hepatocellular Carcinoma [J]. Gastroenterology,2018, 155 (6): 1936-1950.e1917.
[155] Tan N H,Chen B. Treg/Th17
Cell Balance in Patients with Hepatitis B Virus-Related Acute-on-Chronic
Liver Failure at Different Disease Stages [J]. 2021, 2021: 9140602.
[156] Fang Y, Yuan X D, Liu H H,
Xiang L, Chen L M, Fan Y C, et al.Wang K. 5-Aza-2’-deoxycytidine may
enhance the frequency of T regulatory cells from CD4(+) naïve T cells
isolated from the peripheral blood of patients with chronic HBV
infection [J]. Expert Rev Clin Immunol, 2021, 17 (2):
177-185.